x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230169
| Product Information | |
|---|---|
| CAS No. | 906093-29-6 |
| Synonyms | Teneligliptin hydrobromide anhydrous |
| Formula | C22H30N6ORS |
| Molecular Weight | 628.86 |
| SMILES | CC1=N[N](C2=CC=CC=C2)C(=C1)N3CCN(CC3)C4CNC(C4)C(=O)N5CCSC5 |
| Product Description | Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. |
| Format & Storage | |
|---|---|
| Purity | > 97% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
